Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for mining industry professionals · Monday, August 15, 2022 · 586,064,131 Articles · 3+ Million Readers

Cancer Monoclonal Antibodies Market Advancements In Technology Creates Opportunities For Personalized Medicine

Cancer Monoclonal Antibodies Market 2022 - Opportunities And Strategies – Forecast To 2030

Cancer Monoclonal Antibodies Market 2022 - Opportunities And Strategies – Global Forecast To 2030

The Business Research Company’s Cancer Monoclonal Antibodies Market 2022 – Opportunities And Strategies – Global Forecast To 2030

LONDON, GREATER LONDON, UK, June 28, 2022 / -- Technological advancements such as gene sequencing and target gene selection are used by pharmaceutical companies in the cancer monoclonal antibodies market. The increase in adoption of genome wide analysis, global tumor expression profiling and artificial intelligence is promoting opportunities for improved target selection and personalized medicine which is shaping the cancer monoclonal antibodies market outlook. Various powerful techniques such as hybridoma technology, phage display, and B-cell amplification with the help of PCR have been developed for the construction of numerous types of antibodies and antibody fragments with widespread structural modifications. Scientists developed various hybridoma technologies, which involve the fusion of antibody-producing cells—clones of a unique antibody-producing parent cell—with immortalized myeloma tumor cells. Combinations of tumor-targeted mAbs with ICB (Immune checkpoint blockade) have demonstrated that there are several encouraging avenues for maximizing the clinical benefit of mAb therapy. These technologies have led to the development of highly-effective monoclonal antibodies, which are gaining widespread preference among healthcare professionals.

Read more on the Global Cancer Monoclonal Antibodies Market Report

The global cancer monoclonal antibodies market size is expected to grow from $53.78 billion in 2020 to $86.06 billion in 2025 at a rate of 9.9%. The global cancer monoclonal antibodies market share is then expected to grow at a CAGR of 7.3% from 2025 and reach $122.28 billion in 2030.

The rising prevalence of cancer cases across the globe is likely to contribute to the cancer monoclonal antibodies industry growth during the forecast period. According to the Union for International Cancer Control (UICC)’s GLOBOCAN 2020: New Global Cancer Data published in December 2020, the global cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020. As suggested by the new estimates, more than 50 million people are living within five years of a past cancer diagnosis. According to the cancer monoclonal antibodies market research, socio-economic risk factors and the elderly population are a major cause for increasing cancer cases, thereby driving the growth of the cancer MAbs market.

Major players covered in the global cancer monoclonal antibodies industry are F. Hoffmann-La Roche Ltd, Merck & Co., Inc, Bristol Myers Squibb Company, Johnson & Johnson, Amgen Inc.

TBRC’s cancer monoclonal antibodies market report is segmented by monoclonal antibody therapies into Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta, others, by application into breast cancer, blood cancer, lung cancer, brain tumor, colorectal cancer, cervical cancer, gastric cancer, others, by end-user into hospitals & clinics, research laboratories, others.

Cancer Monoclonal Antibodies Market 2022 – By Monoclonal Antibody Therapies (Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta), By Application (Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor, Colorectal Cancer, Cervical Cancer, Gastric Cancer), By End-User (Hospitals, Research Laboratories), And By Region, Opportunities And Strategies – Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provides a cancer monoclonal antibodies market overview, forecast cancer monoclonal antibodies market size and growth for the whole market, cancer monoclonal antibodies market segments, geographies, cancer monoclonal antibodies market trends, cancer monoclonal antibodies market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request for a Sample of the Global Cancer Monoclonal Antibodies Market Report

Not what you were looking for? Here is a list of similar reports by The Business Research Company:
Monoclonal Antibodies (MAbs) Global Market Report 2022 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular), By End-User (Hospitals, Private Clinics, Research Institute) – Market Size, Trends, And Global Forecast 2022-2026

Biosimilars Market 2022 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormone), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases), And By Region, Opportunities And Strategies – Global Forecast To 2030

Cancer Biologics Global Market Report 2022 – By Type (Monoclonal Antibodies, Vaccines, Cell And Gene Therapy), By Application (Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers), By Distribution Channel (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2022-2026

About The Business Research Company?
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Read more about us at

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Check out our:

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
Visit us on social media:

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release